This led to a number of recent studies utilizing Sclerostin-neutralizing antibodies in animals [50], [51], [52] and humans [53], [54] showing that neutralization of Sclerostin can restore bone density in osteoporosis models [50] or other conditions resulting in bone loss [55], [56], [57], [58], [59]. The gene discussed is SOST; the disease is osteoporosis.